BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reshitko GS, Yamansarov EY, Evteev SA, Lopatukhina EV, Shkil' DO, Saltykova IV, Lopukhov AV, Kovalev SV, Lobov AN, Kislyakov IV, Burenina OY, Klyachko NL, Garanina AS, Dontsova OA, Ivanenkov YA, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor. Bioconjug Chem 2020;31:1313-9. [PMID: 32379426 DOI: 10.1021/acs.bioconjchem.0c00202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Warrier DU, Dhanabalan AK, Krishnasamy G, Kolge H, Ghormade V, Gupta CR, Ambre PK, Shinde UA. Novel derivatives of arabinogalactan, pullulan & lactobionic acid for targeting asialoglycoprotein receptor: Biomolecular interaction, synthesis & evaluation. Int J Biol Macromol 2022;207:683-99. [PMID: 35248606 DOI: 10.1016/j.ijbiomac.2022.02.176] [Reference Citation Analysis]
2 Zhu Y, Cao S, Zhang S, Liu J. Recent research progress in galactose-based hepatocyte-targeting fluorescent probes. Dyes and Pigments 2021;196:109799. [DOI: 10.1016/j.dyepig.2021.109799] [Reference Citation Analysis]
3 Wang M, Li Z, Liu F, Yi Q, Pu C, Li Y, Luo T, Liang J, Wang J. Development of Asialoglycoprotein-Mediated Hepatocyte-Targeting Antitumor Prodrugs Triggered by Glutathione. J Med Chem 2021;64:14793-808. [PMID: 34595917 DOI: 10.1021/acs.jmedchem.1c01365] [Reference Citation Analysis]
4 Dai X, Zeng Y, Zhang H, Gu Z, Gong Q, Luo K. Advances on Nanomedicines for Diagnosis and Theranostics of Hepatic Fibrosis. Adv NanoBio Res 2021;1:2000091. [DOI: 10.1002/anbr.202000091] [Reference Citation Analysis]
5 Yamansarov EY, Lopatukhina EV, Evteev SA, Skvortsov DA, Lopukhov AV, Kovalev SV, Vaneev AN, Shkil' DO, Akasov RA, Lobov AN, Naumenko VA, Pavlova EN, Ryabaya OO, Burenina OY, Ivanenkov YA, Klyachko NL, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. Discovery of Bivalent GalNAc-Conjugated Betulin as a Potent ASGPR-Directed Agent against Hepatocellular Carcinoma. Bioconjug Chem 2021;32:763-81. [PMID: 33691403 DOI: 10.1021/acs.bioconjchem.1c00042] [Reference Citation Analysis]
6 Gonzalez-Valdivieso J, Girotti A, Schneider J, Arias FJ. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation. Int J Pharm 2021;599:120438. [PMID: 33662472 DOI: 10.1016/j.ijpharm.2021.120438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Petrov RA, Mefedova SR, Yamansarov EY, Maklakova SY, Grishin DA, Lopatukhina EV, Burenina OY, Lopukhov AV, Kovalev SV, Timchenko YV, Ondar EE, Ivanenkov YA, Evteev SA, Vaneev AN, Timoshenko RV, Klyachko NL, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. New Small-Molecule Glycoconjugates of Docetaxel and GalNAc for Targeted Delivery to Hepatocellular Carcinoma. Mol Pharm 2021;18:461-8. [PMID: 33264010 DOI: 10.1021/acs.molpharmaceut.0c00980] [Reference Citation Analysis]